磷酸二酯酶5抑制剂会增加根治性前列腺切除术后生化复发风险吗?
本研究基于2009年1月至2020年12月机构数据库,分析4630例根治性前列腺切除术后患者,其中776例出现生化复发。多变量Cox模型显示,任何PDE5i使用(HR 1.05,95%CI 0.84,1.31,P=0.7)及第一年使用时长(每1个月HR 0.98,95%CI 0.96,1.00,P=0.055)均未显示增加生化复发风险。结论认为PDE5i处方可仅基于生活质量考虑,患者可放心使用。
要点
- 根治性前列腺切除术后使用PDE5i未显示增加生化复发风险(HR 1.05,95%CI 0.84,1.31,P=0.7)。
- 第一年PDE5i使用时长与生化复发风险无显著关联(每1个月HR 0.98,95%CI 0.96,1.00,P=0.055)。
- PDE5i处方可仅基于生活质量考虑,患者可放心使用不增加生化复发风险。
核心结论
- 根治性前列腺切除术后处方PDE5i可仅基于生活质量考虑,使用PDE5i不增加生化复发风险,患者可放心。
研究设计与样本
- 回顾性机构数据库分析,纳入2009年1月至2020年12月接受根治性前列腺切除术的前列腺癌患者4630例,其中776例出现生化复发。
主要发现
- 生化复发定义为2次PSA测量大于0.1 ng/mL。
- 无生化复发患者中位随访27个月(IQR 12,49)。
- 89%的患者报告在根治性前列腺切除术后第一年12个月内任何时间使用过PDE5i,60%报告在术后一年内使用6个月或以上。
- 任何PDE5i使用与生化复发风险增加无关(HR 1.05,95%CI 0.84,1.31,P=0.7)。
- 第一年PDE5i使用时长与生化复发风险无关(每1个月HR 0.98,95%CI 0.96,1.00,P=0.055)。
关键数值与推荐
- PDE5i暴露采用0至3分评估:0为从不使用,1为有时使用,2为规律使用,3为常规使用。
- 使用PDE5i的患者基线肿瘤学风险较低,但组间差异小,提示残余混杂不太可能掩盖与生化复发的因果关系。
临床怎么用
- 根治性前列腺切除术后处方PDE5i可仅基于生活质量考虑。
- 接受PDE5i的患者可放心,其使用不增加生化复发风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There have been conflicting studies on the association between phosphodiesterase type 5 inhibitor (PDE5i) use and biochemical recurrence (BCR) following radical prostatectomy (RP). Our aim was to determine whether PDE5i drug exposure after RP increases the risk of BCR in patients undergoing RP. MATERIALS AND METHODS: An institutional database of prostate cancer patients treated between January 2009 and December 2020 was reviewed. BCR was defined as 2 PSA measurements greater than 0.1 ng/mL. PDE5i exposure was defined using a 0 to 3 scale, with 0 representing never use, 1 sometimes use, 2 regularly use, and 3 routinely use. The risk of BCR with any PDE5i exposure, the quantity of exposure, and the duration of PDE5i exposure were assessed by multivariable Cox proportional hazards models. RESULTS: The sample size included 4630 patients to be analyzed, with 776 patients having BCR. The median follow-up for patients without BCR was 27 (IQR 12, 49) months. Eighty-nine percent reported taking a PDE5i at any time during the first 12 months after RP, and 60% reported doing so for 6 or more months during the year after RP. There was no evidence of an increase in the risk of BCR associated with any PDE5i use (HR 1.05, 95% CI 0.84, 1.31, P = .7) or duration of PDE5i use in the first year (HR 0.98 per 1 month duration, 95% CI 0.96, 1.00, P = .055). Baseline oncologic risk was lower in patients using PDE5i, but differences between groups were small, suggesting that residual confounding is unlikely to obscure any causal association with BCR. CONCLUSIONS: Prescription of PDE5i to men after RP can be based exclusively on quality of life considerations. Patients receiving PDE5is can be reassured that their use does not increase the risk of BCR.
引用
- Flores JM, Vertosick E, Jenkins LC, et al. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy? J Urol. 2024. PMID: 38194487. doi:10.1097/JU.0000000000003823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。